Neurocrine Biosciences Inc/ US64125C1099 /
| 2024-04-19 4:32:03 PM | Chg. -0.7500 | Volume | Bid4:32:03 PM | Ask4:32:03 PM | High | Low |
|---|---|---|---|---|---|---|
| 131.7900USD | -0.57% | 62,819 Turnover: 5.54 mill. |
131.6400Bid Size: 400 | 131.8300Ask Size: 100 | 133.6500 | 131.5400 |
GlobeNewswire
04-16
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel C...
GlobeNewswire
04-16
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration ...
GlobeNewswire
04-16
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568
GlobeNewswire
03-26
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
03-13
Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer
GlobeNewswire
02-29
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corpo...
GlobeNewswire
02-28
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
GlobeNewswire
02-26
Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Atax...
GlobeNewswire
02-20
Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for A...
GlobeNewswire
02-13
Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023
GlobeNewswire
01-03
Voyager Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
01-02
Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Ad...
GlobeNewswire
2023-12-06
Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Scler...
GlobeNewswire
2023-12-06
Sosei Heptares’ Partner Neurocrine Biosciences Confirms its Plans to Evaluate Two New Muscarinic Ago...
GlobeNewswire
2023-11-10
Sosei Heptares Operational Highlights and Consolidated Results for the Third Quarter and First Nine ...
GlobeNewswire
2023-11-09
Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences
GlobeNewswire
2023-11-08
Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
GlobeNewswire
2023-11-06
Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results
GlobeNewswire
2023-10-30
Voyager Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
GlobeNewswire
2023-09-25
Voyager Therapeutics to Present at the Chardan Genetic Medicines Conference
GlobeNewswire
2023-09-12
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects o...
GlobeNewswire
2023-09-07
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
